IDO1 and breast cancer: Correlation of IDO1 expression with clinicopathological parameters revealed that IDO1 characterizes the two molecular subtypes of BC mostly associated to the expression of the immune checkpoint inhibitors (PD-L1 and CTLA4), basal squamous and luminal infiltrated BC (Fig. 2D).